Triptans are contraindicated for anyone with a history of heart disease, stroke, uncontrolled high blood pressure, or peripheral artery disease. These are the major groups, but the full list also includes people with certain migraine subtypes, severe liver or kidney disease, and adults over 65. Because triptans work partly by narrowing blood vessels, the core concern is the same across most of these groups: constricting arteries that are already compromised can trigger a heart attack, stroke, or dangerous loss of blood flow.
Heart Disease and Coronary Artery Problems
The most significant contraindication is cardiovascular disease. FDA labeling for the entire triptan class lists coronary artery disease, coronary artery vasospasm (Prinzmetal’s angina), and a history of heart attack as reasons not to use these medications. Lab and clinical studies have shown that triptans can constrict coronary arteries, and heart attacks have been reported after triptan use in susceptible people.
Even if you haven’t been diagnosed with heart disease, your prescriber should evaluate your cardiovascular risk before writing a first triptan prescription if you have multiple risk factors. Those include diabetes, high blood pressure, smoking, obesity, older age, and a strong family history of coronary artery disease. Despite these clear warnings, a real-world analysis of insurance claims found that roughly 3.8% of triptan users had a documented diagnosis of ischemic heart disease, suggesting some patients slip through the screening process.
Stroke and Transient Ischemic Attack
Anyone who has had a stroke or a transient ischemic attack (a “mini-stroke”) should not take triptans. The concern is that narrowing blood vessels in the brain, even slightly, could trigger another ischemic event in someone already at elevated risk. Interestingly, research suggests triptans have minimal vasoconstrictor effects on cerebral arteries in most migraine patients, but the risk is considered too high in people with a cerebrovascular history. A case-crossover study published in JAMA Neurology concluded that triptans should not be prescribed to anyone with prior stroke, TIA, or coronary artery disease.
Peripheral Artery Disease and Bowel Ischemia
Peripheral artery disease, where narrowed arteries reduce blood flow to the limbs, is another contraindication. The same vasoconstriction that poses a risk to coronary and cerebral arteries can worsen blood flow in the legs, feet, or arms. Ischemic bowel disease (reduced blood flow to the intestines) is listed on triptan labels as well, because triptans can constrict blood vessels supplying the gut.
Uncontrolled High Blood Pressure
Triptans are off-limits if your blood pressure is uncontrolled. In clinical studies, hypertension is generally defined as a systolic reading of 140 mmHg or higher, or a diastolic reading of 90 mmHg or higher. If your blood pressure is well managed with medication and consistently below those thresholds, triptans may still be an option, but that’s a conversation for your prescriber. The key word in the FDA labeling is “uncontrolled,” meaning blood pressure that remains elevated despite treatment or has never been treated.
Certain Migraine Types
Not all migraines can be treated with triptans. Two subtypes are specifically listed as contraindications in the package inserts: hemiplegic migraine and basilar (brainstem aura) migraine. Hemiplegic migraine causes temporary weakness or paralysis on one side of the body, while basilar migraine produces symptoms like vertigo, double vision, slurred speech, or loss of coordination originating from the brainstem. The concern is that these migraine types may already involve changes in blood flow to critical brain areas, and adding a drug that narrows blood vessels could worsen those effects. Some researchers have questioned whether the basilar migraine restriction is still warranted, but the official labeling has not changed.
Severe Liver or Kidney Disease
Triptans are processed through the liver, the kidneys, or both, depending on the specific drug. Severe liver impairment is a contraindication for the entire class because the body can’t clear the medication properly, leading to dangerously high drug levels. Mild to moderate liver problems may still allow triptan use at a reduced dose.
For kidney impairment, the picture is slightly more nuanced. Severe kidney failure rules out triptans entirely. With moderate impairment, some triptans that are cleared through both the liver and kidneys (frovatriptan and zolmitriptan) may be safer options, though dose adjustments are still necessary. For other triptans that rely more heavily on kidney clearance, dose reductions are required.
Adults Over 65
Clinical guidelines advise against triptan use in people aged 65 and older. The reasoning is straightforward: cardiovascular risk increases with age, and older adults are more likely to have undiagnosed or subclinical heart disease, reduced kidney function, and reduced liver function. All of these factors raise the chance of a serious adverse event. There is limited safety data on triptans in this age group, which reinforces the caution.
Interactions With Antidepressants
In 2006, the FDA issued an alert about the risk of serotonin syndrome when triptans are combined with SSRIs or SNRIs, the two most common classes of antidepressants. Serotonin syndrome is a potentially life-threatening condition caused by too much serotonin activity in the brain, with symptoms ranging from agitation and rapid heart rate to muscle rigidity and seizures. Both triptans and these antidepressants raise serotonin levels through different mechanisms, so combining them could theoretically push levels too high.
That said, the actual risk appears to be quite low. An analysis of the 29 cases that prompted the FDA alert found that the evidence was limited, and many experts concluded the data did not support avoiding the combination altogether. The current consensus is that people taking SSRIs or SNRIs can still use triptans, but should be aware of the symptoms of serotonin syndrome, particularly when starting a new medication or increasing a dose. This isn’t a hard contraindication like cardiovascular disease, but it is a required part of the prescribing information.
Pregnancy and Breastfeeding
Triptans are generally avoided during pregnancy as a precaution, though the data on harm is limited. Among breastfeeding mothers, sumatriptan is considered the best-studied option. Milk levels peak two to four hours after a dose, and the average infant exposure works out to about 0.7% of the mother’s weight-adjusted dose, which is very low. The drug also has poor oral bioavailability, meaning even less of what’s in breast milk gets absorbed by the infant. Sumatriptan is widely considered compatible with breastfeeding, though the manufacturer recommends waiting 12 hours after a dose before nursing. Some experts consider that overly cautious for full-term, healthy infants but reasonable for premature babies.
Options if You Can’t Take Triptans
If you fall into one of these groups, you still have effective options for treating acute migraine. Gepants are a newer class of migraine medication that work by blocking a pain-signaling protein (CGRP) rather than narrowing blood vessels, making them safe for people with cardiovascular disease. Ditans are another newer option that target a different serotonin receptor than triptans, one that doesn’t cause vasoconstriction. Beyond prescription options, over-the-counter pain relievers and anti-nausea medications remain a mainstay for many people who can’t use triptans.